NCT04729959 2026-04-01Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)Phase 2 Active not recruiting59 enrolled